Biotech and pharma catalyst alerts by email

Why this feed exists

The filing tells you a drug program mattered after the market already knows. The catalyst breaks as science news first — a Phase 3 that hit or missed, an approval, a licensing deal, a trial halted for safety. This feed watches drug development across the whole sector, not just the household names, because the next stock to move 100 percent in a day is usually a company most people have never heard of.

What each alert includes

An AI headline stating the actual development, the article excerpt with a link to the full story, and a Market read focused on single-stock impact: the sponsor and its ticker, whether a readout was expected or a surprise, the size of the move comparable events have produced, and the read-through to competitors working the same mechanism.

What we filter, honestly

Drug development produces a constant stream of incremental pipeline news. This feed prioritizes the inflection points — pivotal-trial results, regulatory decisions, and major deals — and scores routine updates lower so a genuine catalyst is not buried.

What it costs

Your first feed is free.